Revvity, Inc. · RVTY · Next earnings

Revvity, Inc. reports Monday, Oct 26, 2026

RVTY reports before market open with consensus EPS at $1.28 and revenue at $694.4M. Last quarter: Revvity Beats Q1 Estimates, Divests China Diagnostics, Raises Guidance

Reports Before market open36 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.28 Calendar consensus
Consensus revenue $694.4M Calendar consensus
Report date Oct 26, 2026 Monday, date estimated
Session Before market open 36 days away

Where RVTY left off: FY2026 Q1

Full report

Revvity Beats Q1 Estimates, Divests China Diagnostics, Raises Guidance

EPS surprise +3.9% Reported $1.06 vs $1.02
Revenue surprise +1.0% Reported $711.1M vs $704.1M
Stock move +6.7% Event window
Subsequent drift +9.5% Up to 20 sessions

Guidance sentiment shifted from maintained (Q4 FY2025) to raised. The company reaffirmed full-year 2026 targets of 2-3% organic growth, revenue of $2.96-$2.99 billion, and adjusted EPS of $5.35-$5.45. The pro-forma operating margin target was lifted to 28.4% from the prior 28%, reflecting the China divestiture's margin benefit and the completion of cost-efficiency programs by mid-year.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Policy-driven headwinds and pricing pressure in the China diagnostics market could affect remaining operations and divestiture timing.
  • Pharma and academic budget cycle uncertainty may weigh on reagent and instrument demand.
  • Execution risk on cost-efficiency initiatives and AI-driven productivity gains.
  • Potential regulatory approval delays for the China divestiture.
  • Long-term birth-rate decline could pressure reproductive-health growth.

Questions analysts left open

  • Cadence and expected 20% Q2 decline in software revenue due to seasonality and competitive comps.
  • Timing, certainty, and financial impact of the China immunodiagnostics divestiture.
  • Sustainability of pharma/biotech spending and academic budget recovery.
  • Capital allocation after divestiture and potential future M&A activity.
  • Margin outlook and whether cost-efficiency initiatives will hit targets on schedule.

Ask FN2 about RVTY next report

Transcript, numbers and history already loaded
What should I watch for in RVTY's next earnings report?How did RVTY guide last quarter, and is consensus above or below that?Give me the bull and bear case going into RVTY earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the RVTY recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent RVTY quarters

All RVTY earnings
+6.7%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.